Scarica l'app Stockscreener
3.33
2.06%
-0.07
Dopo l'orario di chiusura:
3.34
0.010
+0.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.40
Aprire:
$3.33
Volume 24 ore:
480.75K
Relative Volume:
0.79
Capitalizzazione di mercato:
$127.87M
Reddito:
$114.20M
Utile/perdita netta:
$-3.08M
Rapporto P/E:
-8.5714
EPS:
-0.3885
Flusso di cassa netto:
$-77.20M
1 W Prestazione:
-3.20%
1M Prestazione:
-0.30%
6M Prestazione:
-15.48%
1 anno Prestazione:
+104.29%
Intervallo 1D:
$3.24
$3.41
Intervallo di 1 settimana:
$3.225
$3.495
Portata 52W:
$1.38
$7.34
Agenus Inc Stock (AGEN) Company Profile
Nome
Agenus Inc
Settore
Industria
Telefono
781-674-4410
Indirizzo
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.33 | 127.87M | 114.20M | -3.08M | -77.20M | -0.3885 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Iniziato | Robert W. Baird | Outperform |
| 2023-02-28 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-28 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Ripresa | B. Riley FBR | Buy |
| 2019-04-22 | Iniziato | B. Riley FBR | Buy |
| 2016-10-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Reiterato | Maxim Group | Buy |
| 2016-03-11 | Aggiornamento | Maxim Group | Hold → Buy |
| 2015-12-16 | Iniziato | Jefferies | Buy |
| 2015-10-27 | Downgrade | Maxim Group | Buy → Hold |
| 2015-07-27 | Reiterato | MLV & Co | Buy |
| 2015-06-11 | Iniziato | Oppenheimer | Outperform |
| 2015-01-12 | Reiterato | Maxim Group | Buy |
| 2015-01-09 | Reiterato | MLV & Co | Buy |
| 2015-01-09 | Reiterato | Maxim Group | Buy |
| 2014-12-19 | Reiterato | Maxim Group | Buy |
| 2014-05-08 | Reiterato | Maxim Group | Buy |
| 2014-03-14 | Reiterato | MLV & Co | Buy |
| 2013-10-08 | Reiterato | Maxim Group | Buy |
| 2012-01-05 | Iniziato | William Blair | Outperform |
| 2011-12-01 | Iniziato | Global Hunter Securities | Buy |
Mostra tutto
Agenus Inc Borsa (AGEN) Ultime notizie
Agenus (AGEN) presents new phase 1b clinical data on BOT/BAL combination for MSS mCRC - msn.com
Buybacks Report: How sensitive is Agenus Inc to inflation2026 Sector Moves & AI Based Trade Execution Alerts - baoquankhu1.vn
Setup Watch: Can Agenus Inc deliver consistent EPS growth2026 Biggest Moves & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Weekly Earnings: Should you avoid Agenus Inc stock right nowPortfolio Performance Report & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Agenus receives $20M payment under Zydus Life Sciences collaboration - msn.com
Everything Important About Agenus (AGEN) Receiving a Strong Buy Rating Upgrade - bitget.com
Agenus unveils Phase II data for BOT BAL and MiNK iNKT therapy in PD-1 refractory cancer - Traders Union
Can Agenus (AGEN) Run Higher on Rising Earnings Estimates? - Yahoo Finance
All You Need to Know About Agenus (AGEN) Rating Upgrade to Strong Buy - Yahoo Finance
Why Agenus (AGEN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Phase 3 BATTMAN Trial Launches BOT/BAL in MSS or pMMR Metastatic Colorectal Cancer - Oncodaily
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 - The AI Journal
HC Wainwright Analysts Boost Earnings Estimates for Agenus - MarketBeat
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer - 뉴스와이어
Has Agenus (AGEN) Surpassed Other Healthcare Stocks So Far This Year? - bitget.com
Agenus Inc. (AGEN) stock price, news, quote and history - Yahoo Finance UK
Agenus (NASDAQ: AGEN) director awarded 2,448 Deferred Stock Units as board pay - Stock Titan
Agenus Inc. Initiates Landmark Phase 3 BATTMAN Trial In MSS Metastatic Colorectal Cancer - BioPharma APAC
Portfolio Update: Is Agenus Inc benefiting from interest rate changes2026 Final Week & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Agenus begins phase 3 trial for colorectal cancer treatment By Investing.com - Investing.com Australia
Agenus Enrolls First Patient in Phase 3 BATTMAN Trial for MSS/pMMR Metastatic Colorectal Cancer - Oncodaily
Agenus (AGEN) Launches Global Phase 3 Trial for Innovative Cance - GuruFocus
Agenus (AGEN) Launches Global Phase 3 Trial for Innovative Cancer Treatment - GuruFocus
Agenus Inc Announces First Patient Enrolled In Global Phase 3 BATTMAN Trial Of BOT Plus BAL Immunotherapy Combination In MSS Or PMMR Metastatic Colorectal Cancer - MarketScreener
Can Agenus' BOT + BAL Immunotherapy Turn Cold Tumors Hot? - RTTNews
Agenus Launches Landmark Global Phase 3 Clinical Trial - Intellectia AI
Agenus begins phase 3 trial for colorectal cancer treatment - Investing.com
Agenus AGM: Bot/Bal Combo Targets “Cold” MSS Colorectal Cancer as Phase III BATMAN Trial Launches - Yahoo Finance
Agenus announced that the first patient has been enrolled in its global Phase III Battman trial. - bitget.com
Agenus (NASDAQ:AGEN) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Webcast on Clinical Progress and Global Access Initiatives Set for March 31 – Agenus - oncodaily.com
Agenus Cervical Cancer Trial Terminated: What RaPiDS Means for AGEN Investors - tipranks.com
Agenus Inc. (NASDAQ:AGEN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Agenus Securities Class Action Dismissed, Legal Risks Ease - tipranks.com
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access - BioSpace
Agenus Q4 2025 earnings preview - MSN
[SCHEDULE 13G/A] AGENU... - Stock Titan
Agenus reports dismissal of securities class action lawsuit in Massachusetts By Investing.com - Investing.com South Africa
Agenus reports dismissal of securities class action lawsuit in Massachusetts - Investing.com
Agenus wins dismissal of securities class action in Massachusetts federal court - TradingView
Court dismisses Agenus (AGEN) securities class action, siding with executives - Stock Titan
Agenus Secures Dismissal of Investors’ Cancer Drug Class Action - Bloomberg Law News
Agenus Escapes Investor Fraud Suit Over Cancer Drug - Law360
Agenus (NASDAQ: AGEN) director Armen paid salary in stock grant - Stock Titan
AGEN Technical Analysis | Trend, Signals & Chart Patterns | AGENUS INC (NASDAQ:AGEN) - ChartMill
Agenus (NASDAQ:AGEN) Rating Increased to Buy at Wall Street Zen - marketbeat.com
Agenus Inc Azioni (AGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):